Two centuries of assessing drug risks, The New England Journal of Medicine, vol.367, pp.193-197, 2012. ,
Fostering EMA's transparency policy, European Journal of Internal Medicine, vol.25, pp.681-684, 2014. ,
EMA's transparency seems to be opaque, Lancet, p.1847, 2014. ,
Agomelatine and the brave old world of narrative-based medicine, Evidence-based Mental Health, vol.15, pp.2-3, 2012. ,
EMA Must improve the quality of its clinical trial reports, Clinical Research Edition), vol.342, p.2291, 2011. ,
What is the European Medicines Agency?, Epidemiology and Psychiatric Sciences, vol.21, pp.245-247, 2012. ,
FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol), 2020. ,
Regulatory watch: challenges in drug development for central nervous system disorders: a European Medicines Agency perspective, Nature Reviews. Drug Discovery, vol.15, pp.813-814, 2016. ,
Avoidable waste in the production and reporting of research evidence, Obstetrics and Gynecology, vol.114, pp.1341-1345, 2009. ,
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet, vol.391, pp.1357-1366, 2018. ,
Statistical Power Analysis for the Behavioral Sciences, 2013. ,
US Food and Drug Administration approval of esketamine and brexanolone, The Lancet Psychiatry, vol.6, pp.975-977, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02363651
Living systematic review: 1. Introduction-the why, what, when, and how, Journal of Clinical Epidemiology, vol.91, pp.23-30, 2017. ,
, Clinical Efficacy and Safety : Central Nervous System. London: EMA, EMA, 2018.
, EMA, 2018.
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials, BMJ, p.4737, 2010. ,
, Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. FDA, FDA, 1998.
The impact of European regulatory policies on psychotropic drug prescribing patterns, International Review of Psychiatry, vol.17, pp.199-204, 2005. ,
Esketamine for treatment resistant depression: a trick of smoke and mirrors?, Epidemiology and Psychiatric Sciences, vol.29, p.79, 2019. ,
Reducing waste from incomplete or unusable reports of biomedical research, Lancet, vol.383, pp.267-276, 2014. ,
Does long term use of psychiatric drugs cause more harm than good?, Clinical Research Edition), vol.350, p.2435, 2015. ,
Increasing value and reducing waste in research design, conduct, and analysis, Lancet, vol.383, pp.166-175, 2014. ,
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, The British Journal of Psychiatry: The Journal of Mental Science, vol.203, pp.179-187, 2013. ,
Randomized discontinuation trials: utility and efficiency, Journal of Clinical Epidemiology, vol.46, pp.959-971, 1993. ,
Baclofen and alcohol in France, The Lancet. Psychiatry, vol.5, pp.961-962, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02042387
Approval of esketamine for treatment-resistant depression -Authors' reply. The Lancet, Psychiatry, vol.7, pp.235-236, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02498635
Improving study design for antidepressant effectiveness assessment, International Journal of Methods in Psychiatric Research, vol.22, pp.217-231, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00937782
Evaluation in alcohol use disorders -insights from the nalmefene experience, BMC Medicine, vol.14, p.119, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01380423
Attacks on antidepressants: signs of deep-seated stigma? The Lancet, Psychiatry, vol.1, pp.102-104, 2014. ,
New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base, Epidemiology and Psychiatric Sciences, vol.26, pp.231-233, 2017. ,
Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials, PLoS Medicine, vol.12, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01255842
Selective publication of antidepressant trials and its influence on apparent efficacy, The New England Journal of Medicine, vol.358, pp.252-260, 2008. ,
A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results, JAMA Internal Medicine, vol.12, pp.554-560, 2017. ,
Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial, The American Journal of Psychiatry, vol.162, pp.1370-1372, 2005. ,